Common Questions Regarding LOXO-101

Common Questions Regarding LOXO-101

AnnualMeeting2017

3 years
721 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
David Michael Hyman, MD of Memorial Sloan-Kettering explains common questions physicians ask him concerning his study on the efficacy of larotrectinib (LOXO-101). This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. LBA2501: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers
Up Next Autoplay